卡托普利联合罗格列酮对早期糖尿病肾病疗效的观察

目的观察卡托普利联合罗格列酮对早期糖尿病肾病的疗效。方法将60例早期糖尿病肾病患者随机分为治疗组和对照组,每组30例。在控制血糖的同时,对照组给予卡托普利25mg口服,每日3次;治疗组在对照组基础上联用罗格列酮4mg口服,每日1次。疗程均为3个月。治疗前后测定空腹血糖(FPG)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、尿微量白蛋白(ALB)、收缩压(SBP)、舒张压(DBP)。结果治疗组治疗后尿ALB、FPG明显下降,与对照组治疗后比较差异有统计学意义(P<0.05),治疗组治疗后TC、TG、HDL、LDL、SBP、DBP与对照组治疗后比较差异均无统计学意义(P>0.05)。结论卡托普利联合罗格列酮能更有效地降低早期糖尿病肾病患者尿微量白蛋白的排泄,对早期糖尿病肾病有保护作用。

Therapeutic effect of captopril combined with rosiglitazone on ea rly diabetic nephropathy

Objective To observe the therapeutic effect of captopril combined with rosiglitazone on early diabetic nephropathy.Methods 60 patients with early diabetic nephropathy were randomly divided into treatment group and control group.On the basis of controlling blood sugar,30 patients in control group were treated by captopril 25mg once,three times a day,while the other 30 patients in treatment group,on the basis of the control group,were treated by rosiglitazone 4 mg daily for oral dose,with a treatment course of 3 months for both groups.The fasting plasma glucose(FPG),total cholesterol(TC),triglycerides(TG),high-density lipoprotein-cholesterol(HDL-C),low density lipoprotein-cholesterol(LDL-C),urinary albumin(ALB),systolic blood pressure(SBP),diastolic blood pressure(DBP)were detected before and after treatment for both groups.Results After treatment the urinary ALB and FPG in treatment group were decreased significantly,as compared with those of control group(P<0.05),however,there was no significant difference in TC,TG,HDL-C,LDL-C,SBP and DBP between two groups(P>0.05).Conclusion The captopril combined rosiglitazone has a protective effect on early diabetic nephropathy,which can reduce the urinary excretion of albumin more effectively in patients with early diabetic nephropathy.